[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365908-105":59,"doc-detail-365908-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","trends-in-immunotherapy-io-use-and-survival-among-patients-with-high-incidence-stage-iv-cancers-across-the-united-states","Trends in Immunotherapy (IO) Use and Survival Among Patients With High-Incidence Stage IV Cancers Across the United States","","Immunotherapy (IO) has reshaped cancer care, yet real-world adoption in advanced disease varies by tumor type. This study evaluates IO use and survival trends for U.S. Stage IV patients across high-incidence cancers. Using National Cancer Database data from 2004–2020, the analysis compares three diagnosis periods and estimates IO and overall survival with statistical survival methods. IO use rose from 1.0% to 24.6%, with melanoma showing the largest gains.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/trends-in-immunotherapy-io-use-and-survival-among-patients-with-high-incidence-stage-iv-cancers-across-the-united-states/365908/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/trends-in-immunotherapy-io-use-and-survival-among-patients-with-high-incidence-stage-iv-cancers-across-the-united-states/365908.png","ImageObject",300,407,{"name":92,"@type":93},"Fahsai","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which cancer types were included in the study’s Stage IV cohorts?","Question",{"text":112,"@type":113},"Stage IV prostate, breast, melanoma, colorectal, renal, bladder, lung, and pancreas cancers were included using National Cancer Database records.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did IO use change across the three diagnosis periods?",{"text":117,"@type":113},"IO use increased over time, rising from 1.0% to 24.6% overall, with melanoma increasing from 9.5% to 58.5%.",{"name":119,"@type":110,"acceptedAnswer":120},"Which cancer type showed the greatest survival improvement?",{"text":121,"@type":113},"Melanoma showed the largest survival gains, with median survival increasing from 7.1 to 14.9 months and the biggest improvement in 3-year overall survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365908,1790466735,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","Journal of  \nSurgical Oncology  \nRESEARCH ARTICLE   \nTrends in Immunotherapy (IO) Use and Survival Among Patients With High‐Incidence Stage IV Cancers Across the United States  \nSamantha C. Warwar1,2 | Lauren M. Janczewski1,2 | Gladys M. Rodriguez3 | Jeffrey D. Wayne1,4 | David J. Bentrem1,2,4   \n1Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA | 2Northwestern Quality Improvement, Research, & Education in Surgery (NQUIRES), Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA | 3Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA | 4Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA  \nCorrespondence: Samantha C. Warwar ([samantha.warwar@nm.org](samantha.warwar@nm.org))  \nReceived: 19 December 2024 | Accepted: 29 December 2024  \nFunding: This work is supported by the National Institutes of Health training.  \nKeywords: advanced cancer therapy | immunotherapy | melanoma | neoplasms by site | survival disparities  \nABSTRACT  \nBackground and Objectives: IO has transformed cancer management, but its adoption in advanced cancer patients varies by tumor type. With more Stage IV patients undergoing surgery, understanding site‐specific outcomes in these challenging patients is essential. We aimed to evaluate IO use and survival trends for Stage IV cancer patients across high‐incidence cancers in the US. Methods: Patients diagnosed with Stage IV prostate, breast, melanoma, colorectal, renal, bladder, lung, or pancreas cancer were identified from the National Cancer Database (2004–2020) . Cochrane–Armitage test and Kaplan–Meier methods assessed IO and overall survival across three periods: 2004–2010, 2011–2015, and 2016–2020.  \nResults: Among 1 425 731 Stage IV cancer patients, most had lung (50.0%), pancreas (12.5%), and breast cancer (9.3%), while the least had melanoma (2.2%) . From periods 1 to 3, IO use increased from 1.0% to 24.6%, notably in melanoma (9.5% to 58.5%, p \u003C 0.001) . Melanoma exhibited the greatest survival gains (median survival: 7.1 to 14.9 months) . Absolute increases in 3‐year overall survival rates ranged from 3.4% in pancreas (1.7% to 5.1%) to 21.4% in melanoma (15.7% to 37.1%) .  \nConclusions: Utilization of IO is tumor‐site specific and associated with improved survival rates for Stage IV cancer, with varied success across types. Variations in receipt highlight ongoing challenges to ensure equitable adoption.  \n1 | Introduction  \nIO marks a pivotal shift in the landscape of cancer treatment, offering the potential for improved outcomes where traditional therapies have had limited efficacy. The advancement in IO has notably enhanced the prognostic landscape for certain difficult‐to‐treat cancers, particularly significant for individuals with advanced‐stage cancer who frequently face  \nlimited effective treatment options and poor prognosis [1] . Important milestones for metastatic melanoma began with the Food and Drug Administration (FDA) approval of ipilimumab (Yervoy), a CTLA‐4 inhibitor, in 2011 [2], later augmented by the addition of PD‐1 inhibitors in 2014 [3] . These breakthroughs have led to a substantial increase in the 3‐year survival rate for patients with advanced melanoma, escalating from 22% in 2010–2012 to 34% in 2015–2017 [4] . Similarly, data  \n\n| Abbreviations: CI, confidence interval; CoC, American College of Surgeons Commission on Cancer; FDA, Food and Drug Administration; IO, immunotherapy; NCDB, National Cancer Database; OR, odds ratio. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2025 The Author(s) . Journal of Surgical Oncology published by Wiley Periodicals LLC. |\n\nJournal of Surgical Oncology, 2025; 131:1455–1466 1455 of ","cbCailnhtP389cMy","https://ap.wps.com/l/cbCailnhtP389cMy","pdf",646908,12,"English","# Abstract\n## Background and Objectives\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Materials and Methods\n## Data Source and Study Population","[{\"question\":\"Which cancer types were included in the study’s Stage IV cohorts?\",\"answer\":\"Stage IV prostate, breast, melanoma, colorectal, renal, bladder, lung, and pancreas cancers were included using National Cancer Database records.\"},{\"question\":\"How did IO use change across the three diagnosis periods?\",\"answer\":\"IO use increased over time, rising from 1.0% to 24.6% overall, with melanoma increasing from 9.5% to 58.5%.\"},{\"question\":\"Which cancer type showed the greatest survival improvement?\",\"answer\":\"Melanoma showed the largest survival gains, with median survival increasing from 7.1 to 14.9 months and the biggest improvement in 3-year overall survival.\"}]","Trends in Immunotherapy (IO) Use and Survival Among Patients With High-Incidence Stage IV Cancers Across the United States | PDF",1790162890,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6bdcb3838fa8c16f49c46e7120110bd.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/583d1cdbda8c006ca0894bb80753bd6f.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0cfc54ea14882b349bb5f65fd396e08.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f0649081c503466c5fc05d09f532ff8.webp",980,1287]